Is AIKI or LUNA more profitable?

Luna Innovations' return on equity of 0.00% beat AIkido Pharma's return on equity. Company Net Margins Return on Equity Return on Assets AIkido Pharma N/A -18.21% -16.94% Luna Innovations N/A N/A N/A

Which has higher earnings and valuation, AIKI or DKDCA?

Data Knights Acquisition is trading at a lower price-to-earnings ratio than AIkido Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AIkido Pharma N/A N/A -$7.17M -$3.88 N/A Data Knights Acquisition N/A N/A $340K -$0.19 N/A

Is AIKI or DKDCA more profitable?

Data Knights Acquisition's return on equity of 0.00% beat AIkido Pharma's return on equity. Company Net Margins Return on Equity Return on Assets AIkido Pharma N/A -18.21% -16.94% Data Knights Acquisition N/A N/A -5.55%

Do analysts rate CING or AIKI?

Cingulate presently has a consensus target price of $27.33, suggesting a potential upside of 461.26%. Given Cingulate's stronger consensus rating and higher probable upside, analysts plainly believe Cingulate is more favorable than AIkido Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cingulate 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 AIkido Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation & earnings, CING or AIKI?

Cingulate is trading at a lower price-to-earnings ratio than AIkido Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cingulate N/A N/A -$22.45M -$4.23 N/A AIkido Pharma N/A N/A -$7.17M -$3.88 N/A

Is CING or AIKI more profitable?

AIkido Pharma's return on equity of -18.21% beat Cingulate's return on equity. Company Net Margins Return on Equity Return on Assets Cingulate N/A -365.15% -158.55% AIkido Pharma N/A -18.21% -16.94%

Do analysts recommend AIKI or BYSI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AIkido Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is AIKI or BYSI more profitable?

BeyondSpring's return on equity of 0.00% beat AIkido Pharma's return on equity. Company Net Margins Return on Equity Return on Assets AIkido Pharma N/A -18.21% -16.94% BeyondSpring N/A N/A -14.00%

Do analysts rate EXOZ or AIKI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AIkido Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is EXOZ or AIKI more profitable?

AIkido Pharma's return on equity of -18.21% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets eXoZymes N/A -220.63% -141.26% AIkido Pharma N/A -18.21% -16.94%

AIkido Pharma (AIKI) Competitors

$3.16 -0.05 (-1.56%)

As of 06/12/2026

Compare

AIKI vs. LUNA, DKDCA, CING, BYSI, and EXOZ

Should you buy AIkido Pharma stock or one of its competitors? MarketBeat compares AIkido Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AIkido Pharma include Luna Innovations (LUNA), Data Knights Acquisition (DKDCA), Cingulate (CING), BeyondSpring (BYSI), and eXoZymes (EXOZ).

How does AIkido Pharma compare to Luna Innovations?

AIkido Pharma (NASDAQ:AIKI) and Luna Innovations (NASDAQ:LUNA) are both small-cap commercial physical research industry companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

Luna Innovations' return on equity of 0.00% beat AIkido Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AIkido Pharma	N/A	-18.21%	-16.94%
Luna Innovations	N/A	N/A	N/A

10.9% of AIkido Pharma shares are held by institutional investors. Comparatively, 87.5% of Luna Innovations shares are held by institutional investors. 8.6% of AIkido Pharma shares are held by company insiders. Comparatively, 7.6% of Luna Innovations shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Luna Innovations has higher revenue and earnings than AIkido Pharma. AIkido Pharma is trading at a lower price-to-earnings ratio than Luna Innovations, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AIkido Pharma	N/A	N/A	-$7.17M	-$3.88	N/A
Luna Innovations	$116.61M	0.35	$9.28M	$0.03	39.67

AIkido Pharma has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market. Comparatively, Luna Innovations has a beta of 1.9, meaning that its share price is 90% more volatile than the broader market.

In the previous week, AIkido Pharma's average media sentiment score of 0.00 equaled Luna Innovations'average media sentiment score.

Company	Overall Sentiment
AIkido Pharma	Neutral
Luna Innovations	Neutral

Summary

Luna Innovations beats AIkido Pharma on 8 of the 9 factors compared between the two stocks.

How does AIkido Pharma compare to Data Knights Acquisition?

AIkido Pharma (NASDAQ:AIKI) and Data Knights Acquisition (NASDAQ:DKDCA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

AIkido Pharma has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market. Comparatively, Data Knights Acquisition has a beta of 0.18, suggesting that its stock price is 82% less volatile than the broader market.

Data Knights Acquisition is trading at a lower price-to-earnings ratio than AIkido Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AIkido Pharma	N/A	N/A	-$7.17M	-$3.88	N/A
Data Knights Acquisition	N/A	N/A	$340K	-$0.19	N/A

In the previous week, AIkido Pharma's average media sentiment score of 0.00 equaled Data Knights Acquisition'saverage media sentiment score.

Company	Overall Sentiment
AIkido Pharma	Neutral
Data Knights Acquisition	Neutral

10.9% of AIkido Pharma shares are owned by institutional investors. Comparatively, 35.3% of Data Knights Acquisition shares are owned by institutional investors. 8.6% of AIkido Pharma shares are owned by insiders. Comparatively, 45.7% of Data Knights Acquisition shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Data Knights Acquisition's return on equity of 0.00% beat AIkido Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AIkido Pharma	N/A	-18.21%	-16.94%
Data Knights Acquisition	N/A	N/A	-5.55%

Summary

Data Knights Acquisition beats AIkido Pharma on 6 of the 8 factors compared between the two stocks.

How does AIkido Pharma compare to Cingulate?

Cingulate (NASDAQ:CING) and AIkido Pharma (NASDAQ:AIKI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

In the previous week, Cingulate had 13 more articles in the media than AIkido Pharma. MarketBeat recorded 13 mentions for Cingulate and 0 mentions for AIkido Pharma. Cingulate's average media sentiment score of 0.93 beat AIkido Pharma's score of 0.00 indicating that Cingulate is being referred to more favorably in the media.

Company	Overall Sentiment
Cingulate	Positive
AIkido Pharma	Neutral

Cingulate is trading at a lower price-to-earnings ratio than AIkido Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cingulate	N/A	N/A	-$22.45M	-$4.23	N/A
AIkido Pharma	N/A	N/A	-$7.17M	-$3.88	N/A

Cingulate has a beta of -0.85, suggesting that its share price is 185% less volatile than the broader market. Comparatively, AIkido Pharma has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

41.3% of Cingulate shares are owned by institutional investors. Comparatively, 10.9% of AIkido Pharma shares are owned by institutional investors. 5.3% of Cingulate shares are owned by insiders. Comparatively, 8.6% of AIkido Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

AIkido Pharma's return on equity of -18.21% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cingulate	N/A	-365.15%	-158.55%
AIkido Pharma	N/A	-18.21%	-16.94%

Cingulate presently has a consensus target price of $27.33, suggesting a potential upside of 461.26%. Given Cingulate's stronger consensus rating and higher probable upside, analysts plainly believe Cingulate is more favorable than AIkido Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
AIkido Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

AIkido Pharma beats Cingulate on 7 of the 13 factors compared between the two stocks.

How does AIkido Pharma compare to BeyondSpring?

AIkido Pharma (NASDAQ:AIKI) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk.

BeyondSpring's return on equity of 0.00% beat AIkido Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AIkido Pharma	N/A	-18.21%	-16.94%
BeyondSpring	N/A	N/A	-14.00%

AIkido Pharma has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market. Comparatively, BeyondSpring has a beta of 0.43, suggesting that its share price is 57% less volatile than the broader market.

BeyondSpring has higher revenue and earnings than AIkido Pharma. BeyondSpring is trading at a lower price-to-earnings ratio than AIkido Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AIkido Pharma	N/A	N/A	-$7.17M	-$3.88	N/A
BeyondSpring	$1.75M	39.01	-$1.01M	-$0.14	N/A

In the previous week, BeyondSpring had 1 more articles in the media than AIkido Pharma. MarketBeat recorded 1 mentions for BeyondSpring and 0 mentions for AIkido Pharma. BeyondSpring's average media sentiment score of 1.87 beat AIkido Pharma's score of 0.00 indicating that BeyondSpring is being referred to more favorably in the news media.

Company	Overall Sentiment
AIkido Pharma	Neutral
BeyondSpring	Very Positive

10.9% of AIkido Pharma shares are owned by institutional investors. Comparatively, 40.3% of BeyondSpring shares are owned by institutional investors. 8.6% of AIkido Pharma shares are owned by insiders. Comparatively, 29.3% of BeyondSpring shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AIkido Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

BeyondSpring beats AIkido Pharma on 10 of the 12 factors compared between the two stocks.

How does AIkido Pharma compare to eXoZymes?

eXoZymes (NASDAQ:EXOZ) and AIkido Pharma (NASDAQ:AIKI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AIkido Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, eXoZymes had 2 more articles in the media than AIkido Pharma. MarketBeat recorded 2 mentions for eXoZymes and 0 mentions for AIkido Pharma. eXoZymes' average media sentiment score of 0.98 beat AIkido Pharma's score of 0.00 indicating that eXoZymes is being referred to more favorably in the media.

Company	Overall Sentiment
eXoZymes	Positive
AIkido Pharma	Neutral

eXoZymes has a beta of 2.66, meaning that its stock price is 166% more volatile than the broader market. Comparatively, AIkido Pharma has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market.

AIkido Pharma has lower revenue, but higher earnings than eXoZymes. eXoZymes is trading at a lower price-to-earnings ratio than AIkido Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	$70K	931.59	-$9.16M	-$1.14	N/A
AIkido Pharma	N/A	N/A	-$7.17M	-$3.88	N/A

AIkido Pharma's return on equity of -18.21% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-220.63%	-141.26%
AIkido Pharma	N/A	-18.21%	-16.94%

10.9% of AIkido Pharma shares are owned by institutional investors. 72.4% of eXoZymes shares are owned by company insiders. Comparatively, 8.6% of AIkido Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

eXoZymes beats AIkido Pharma on 7 of the 12 factors compared between the two stocks.

Get AIkido Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AIKI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AIKI vs. The Competition

Export

Metric	AIkido Pharma	Commercial physical research Industry	Medical Sector	NASDAQ Exchange
Market Cap	$17.33M	$23.00M	$6.50B	$12.36B
Dividend Yield	N/A	N/A	2.67%	5.67%
P/E Ratio	-0.81	19.83	23.99	24.69
Price / Sales	N/A	0.35	538.03	166.93
Price / Cash	N/A	57.23	27.48	37.92
Price / Book	0.16	0.16	10.47	6.82
Net Income	-$7.17M	-$525K	$3.56B	$337.45M
7 Day Performance	1.94%	-5.05%	1.21%	2.49%
1 Month Performance	-17.92%	-17.41%	2.14%	4.37%
1 Year Performance	-34.98%	30.72%	26.24%	32.80%

AIkido Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AIKI AIkido Pharma	N/A	$3.16 -1.6%	N/A	-35.0%	$17.33M	N/A	N/A	4	High Trading Volume
LUNA Luna Innovations	N/A	$1.16 +10.5%	N/A	+53.3%	$39.39M	$116.61M	38.67	390
DKDCA Data Knights Acquisition	N/A	$0.69 +2.0%	N/A	+68.5%	$3.57M	N/A	N/A	2	Gap Up High Trading Volume
CING Cingulate	3.2565 of 5 stars	$5.03 +2.9%	$27.33 +443.0%	+16.2%	$67.05M	N/A	N/A	20	Gap Up
BYSI BeyondSpring	0.2199 of 5 stars	$1.64 -0.4%	N/A	-43.7%	$66.82M	N/A	N/A	80	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AIKI) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AIkido Pharma (AIKI) Competitors

AIKI vs. LUNA, DKDCA, CING, BYSI, and EXOZ

How does AIkido Pharma compare to Luna Innovations?

Summary

How does AIkido Pharma compare to Data Knights Acquisition?

Summary

How does AIkido Pharma compare to Cingulate?

Summary

How does AIkido Pharma compare to BeyondSpring?

Summary

How does AIkido Pharma compare to eXoZymes?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIKI vs. The Competition

AIkido Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AIkido Pharma (AIKI) Competitors

AIKI vs. LUNA, DKDCA, CING, BYSI, and EXOZ

How does AIkido Pharma compare to Luna Innovations?

Is AIKI or LUNA more profitable?

Do insiders and institutionals hold more shares of AIKI or LUNA?

Which has stronger earnings and valuation, AIKI or LUNA?

Which has more risk & volatility, AIKI or LUNA?

Does the media favor AIKI or LUNA?

Summary

How does AIkido Pharma compare to Data Knights Acquisition?

Which has more volatility and risk, AIKI or DKDCA?

Which has higher earnings and valuation, AIKI or DKDCA?

Does the media refer more to AIKI or DKDCA?

Do institutionals and insiders believe in AIKI or DKDCA?

Is AIKI or DKDCA more profitable?

Summary

How does AIkido Pharma compare to Cingulate?

Does the media refer more to CING or AIKI?

Which has preferable valuation & earnings, CING or AIKI?

Which has more risk and volatility, CING or AIKI?

Do institutionals & insiders believe in CING or AIKI?

Is CING or AIKI more profitable?

Do analysts rate CING or AIKI?

Summary

How does AIkido Pharma compare to BeyondSpring?

Is AIKI or BYSI more profitable?

Which has more risk and volatility, AIKI or BYSI?

Which has better valuation and earnings, AIKI or BYSI?

Does the media prefer AIKI or BYSI?

Do institutionals and insiders have more ownership in AIKI or BYSI?

Do analysts recommend AIKI or BYSI?

Summary

How does AIkido Pharma compare to eXoZymes?

Do analysts rate EXOZ or AIKI?

Does the media refer more to EXOZ or AIKI?

Which has more volatility & risk, EXOZ or AIKI?

Which has higher earnings and valuation, EXOZ or AIKI?

Is EXOZ or AIKI more profitable?

Do institutionals & insiders have more ownership in EXOZ or AIKI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIKI vs. The Competition

AIkido Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools